The antidepressant-like effect of fisetin involves the serotonergic and noradrenergic system

Behavioural Brain Research

Volumn 228, Issue 2, 2012, Pages 359-366

  Zhen, Linlin ^a   Zhu, Jiejin ^b   Zhao, Xin ^c   Huang, Wu ^d   An, Yiran ^e,f   Li, Shan ^b   Du, Xia ^b   Lin, Mengmeng ^b   Wang, Qiandong ^b   Xu, Ying ^f   Pan, Jianchun ^b  

^a THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c NINGBO UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e Morgantown High School   (United States)

^f WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Fisetin; Forced swimming test (FST); Monoamine; Monoamine oxidase (MAO); Tail suspension test (TST)

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); FISETIN; RESERPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; EXPERIMENTAL TEST; FORCED SWIMMING TEST; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHERMIA; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PTOSIS; SEROTONINERGIC SYSTEM; TAIL SUSPENSION TEST;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HINDLIMB SUSPENSION; IMMOBILITY RESPONSE, TONIC; MALE; MICE; MICE, INBRED ICR; MONOAMINE OXIDASE; NOREPINEPHRINE; RANDOM ALLOCATION; SEROTONIN; SWIMMING;

EID: 84856230372     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.12.017     Document Type: Article

References (55)

1. Xu Y., Ku B., Cui L., Li X., Barish P.A., Foster T.C., et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 2007, 1162:9-18.
2. Rybnikova E., Mironova V., Pivina S., Tulkova E., Ordyan N., Nalivaeva N., et al. Involvement of the hypothalamic-pituitary-adrenal axis in the antidepressant-like effects of mild hypoxic preconditioning in rats. Psychoneuroendocrinology 2007, 32:813-823.
3. Kumar B., Kuhad A., Chopra K. Neuropsychopharmacological effect of sesamol in unpredictable chronic mild stress model of depression: behavioral and biochemical evidences. Psychopharmacology (Berl) 2010, 214:819-828.
4. Nemeroff C.B. Stress, menopause and vulnerability for psychiatric illness. Expert Rev Neurother 2007, 7:S11-S13.
5. Mao Q., Huang Z., Ip S., Che C. Antidepressant-like effect of ethanol extract from Paeonia lactiflora in mice. Phytother Res 2008, 22:1496-1499.
6. Deniker P. The search for new antidepressants and related drugs. Monoamine oxidase and diseases, prospects for therapy with reversible inhibitors 1984, 3-8. Academic Press, New York, NY. K.F. Tipton, D. Dostert, M.S. Benedetti (Eds.).
7. Xu Y., Ku B., Tie L., Yao H., Jiang W., Ma X., et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res 2006, 1122:56-64.
8. Heim K.E., Tagliaferro A.R., Bobilya D.J. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem 2002, 13:572-584.
9. Middleton E., Kandaswami C., Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000, 52:673-751.
10. Ross J.A., Kasum C.M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002, 22:19-34.
11. Maher P., Akaishi T., Abe K. Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc Natl Acad Sci USA 2006, 103:16568-16573.
12. Fiorani M., Accorsi A., Cantoni O. Human red blood cells as a natural flavonoid reservoir. Free Radic Res 2003, 37:1331-1338.
13. Brash D.E., Havre P.A. New careers for antioxidants. Proc Natl Acad Sci USA 2002, 99:13969-13971.
14. Ishige K., Schubert D., Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 2001, 30:433-446.
15. Mazzio E.A., Harris N., Soliman K.F. Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med 1998, 64:603-606.
16. Maher P. The flavonoid fisetin promotes nerve cell survival from trophic factor withdrawal by enhancement of proteasome activity. Arch Biochem Biophys 2008, 476:139-144.
17. Maher P. Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes Nutr 2009, 10.1007/s12263-009-0142-5.
18. Maher P., Dargusch R., Bodai L., Gerard P.E., Purcell J.M., Marsh J.L. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet 2011, 20:261-270.
19. Akaishi T., Morimoto T., Shibao M., Watanabe S., Sakai-Kato K., Utsunomiya-Tate N., et al. Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein. Neurosci Lett 2008, 444:280-285.
20. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994, 15:220-226.
21. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., et al. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 2005, 518:40-46.
22. Wang R., Xu Y., Wu H.L., Li Y.B., Li Y.H., Guo J.B., et al. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol 2008, 578:43-50.
23. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
24. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
25. Porsolt R.D., Bertin A., Jalfre M. Behavioural despair in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 1978, 51:291-294.
26. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 2005, 82:200-206.
27. Redrobe J.P., Bourin M., Colombel M.C., Baker G.B. Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms. J Psychopharmacol 1998, 12:348-355.
28. Bourin M., Poncelet M., Chermat R., Simon P. The value of the reserpine test in psychopharmacology. Arzneimittelforschung 1983, 33:1173-1176.
29. Franklin K., Paxinos G. The rat brain in stereotaxic coordinates 1997, Academic Press, San Diego, CA.
30. Nitta A., Furukawa Y., Hayashi K., Hiramatsu M., Kameyama T., Hasegawa T., et al. Denervation of dopaminergic neurons with 6-hydroxydopamine increases nerve growth factor content in rat brain. Neurosci Lett 1992, 144:152-156.
31. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
32. Kulkarni S.K., Dhir A. On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol 2008, 589:163-172.
33. Freitas A.E., Budni J., Lobato K.R., Binfare R.W., Machado D.G., Jacinto J., et al. Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: evidence for the involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:335-343.
34. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005, 29:571-625.
35. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005, 29:547-569.
36. Hemby S.E., Lucki I., Gatto G., Singh A., Thornley C., Matasi J., et al. Potential antidepressant effects of novel tropane compounds, selective for serotonin or dopamine transporters. J Pharmacol Exp Ther 1997, 282:727-733.
37. Reneric J.P., Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 1998, 136:190-197.
38. Yi L.T., Li C.F., Zhan X., Cui C.C., Xiao F., Zhou L.P., et al. Involvement of monoaminergic system in the antidepressant-like effect of the flavonoid naringenin in mice. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1223-1228.
39. Richerson G.B., Buchanan G.F. The serotonin axis: shared mechanisms in seizures, depression, and SUDEP. Epilepsia 2011, 52(Suppl. 1):28-38.
40. Machado R.B., Tufik S., Suchecki D. Chronic stress during paradoxical sleep deprivation increases paradoxical sleep rebound: association with prolactin plasma levels and brain serotonin content. Psychoneuroendocrinology 2008, 33:1211-1224.
41. Xu Y., Wang Z., You W., Zhang X., Li S., Barish P.A., et al. Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol 2010, 20:405-413.
42. Montgomery S.A. Is there a role for a pure noradrenergic drug in the treatment of depression?. Eur Neuropsychopharmacol 1997, 7(Suppl. 1):S3-S9. [discussion S71-3].
43. ++-Atp dependent storage mechanism in the amine granules of the adrenal medulla. Acta Physiol Scand Suppl 1963, (Suppl. 215):1-38.
44. Haggendal J., Dahlstrom A. The recovery of noradrenaline in adrenergic nerve terminals of the rat after reserpine treatment. J Pharm Pharmacol 1971, 23:81-89.
45. Beasley C.M., Holman S.L., Potvin J.H. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 1993, 5:199-207.
46. Wong D.T., Bymaster F.P., Engleman E.A. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 1995, 57:411-441.
47. Burrows G.D., Maguire K.P., Norman T.R. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998, 59(Suppl. 14):4-7.
48. Swann A.C., Bowden C.L., Rush A.J., Rhoades H., Rose R., Kobes R. Desipramine versus phenelzine in recurrent unipolar depression: clinical characteristics and treatment response. J Clin Psychopharmacol 1997, 17:78-83.
49. Bryant S.G., Brown C.S. Current concepts in clinical therapeutics: major affective disorders, Part 1. Clin Pharm 1986, 5:304-318.
50. Johnston J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968, 17:1285-1297.
51. Foley P., Gerlach M., Youdim M.B., Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders. Parkinsonism Relat Disord 2000, 6:25-47.
52. Marek G.J., Seiden L.S. Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior. Psychopharmacology (Berl) 1988, 96:153-160.
53. Kulkarni S.K., Bhutani M.K., Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl) 2008, 201:435-442.
54. Xu Y., Li S., Chen R., Li G., Barish P.A., You W., et al. Antidepressant-like effect of low molecular proanthocyanidin in mice: involvement of monoaminergic system. Pharmacol Biochem Behav 2010, 94:447-453.
55. Abdel-Razaq W., Kendall D.A., Bates T.E. The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem Res 2011, 36:327-338.